Non-randomised, Open Label, Sequential-group Study to Assess the Pharmacokinetics and Pharmacodynamic Effect of Different Multiple Oral Doses of BI 425809 in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 06 Jul 2015
At a glance
- Drugs BI 425809 (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 01 Jul 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 09 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 22 Feb 2015 Planned End Date changed from 1 Jul 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov record.